Skip to search formSkip to main contentSkip to account menu

cyclophosphamide/paclitaxel

Known as: CTX/TAX, Paclitaxel/Cyclophosphamide 
A combination of agents containing cyclophosphamide and paclitaxel.
National Institutes of Health

Related topics

Related topics

3 relations
CyclophosphamidePaclitaxelTaxol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract PD6-09: The immune microenvironment in hormone receptor-positive breast cancer patients and relationship to treatment outcome following preoperative chemotherapy plus bevacizumab
Background: Hormone receptor-positive (HR+) tumors have fewer tumor-infiltrating lymphocytes (TILs) and lower response rates to… 
2016
2016
Preliminary safety results from a multicenter phase II trial of nanoparticle albumin-bound paclitaxel/cyclophosphamide in early stage breast cancer plus trastuzumab in HER-2+ patients (pts).
e11509 Background: Docetaxel/cyclophosphamide has demonstrated superior disease free and overall survival compared to doxorubicin… 
2013
2013
Neoadjuvant bevacizumab: Surgical complications of mastectomy with and without reconstruction.
1100 Background: Neoadjuvant therapy is commonly used in operable breast cancer. We prospectively evaluated the surgical… 
Review
2013
Review
2013
Tolerability and cardiac safety of neo/adjuvant trastuzumab-based chemotherapy regimens for HER2+ breast cancer: A single institution experience.
e11508 Background: Docetaxel/carboplatin/trastuzumab (H) (TCaH) and doxorubicin/cyclophosphamide/paclitaxel/H (AC-TH) and its… 
Review
2011
Review
2011
Responses rates and outcome to neoadjuvant chemotherapy in triple-negative breast cancers (TNBC).
e11522 Background: TNBC are characterized by the lack of both hormonal receptors expression and overexpression of human epidermal… 
1998
1998
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
Paclitaxel is active in metastatic breast cancer. Combination studies have demonstrated complex interactions between paclitaxel… 
1997
1997
Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Relapse following complete remission achieved with a single course of high-dose chemotherapy continues to be the main cause of… 
1997
1997
A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer.
To assess the feasibility of administering sequential cycles of dose-intensive therapy, 14 patients without prior chemotherapy… 
1995
1995
Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated substantial single-agent activity against both… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)